Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats
Top Cited Papers
- 6 April 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 21 (5), 506-511
- https://doi.org/10.1038/nm.3787
Abstract
Two papers show that Ampk and Sirt1 respond to metformin and resveratrol, respectively, in the duodenum to initiate a gut-brain-liver axis that reduces hepatic glucose production, thus explaining the antidiabetic actions of these two class of drugs. Metformin is a first-line therapeutic option for the treatment of type 2 diabetes, even though its underlying mechanisms of action are relatively unclear1,2,3,4,5,6. Metformin lowers blood glucose levels by inhibiting hepatic glucose production (HGP), an effect originally postulated to be due to a hepatic AMP-activated protein kinase (AMPK)-dependent mechanism5,6. However, studies have questioned the contribution of hepatic AMPK to the effects of metformin on lowering hyperglycemia1,3,4, and a gut–brain–liver axis that mediates intestinal nutrient- and hormone-induced lowering of HGP has been identified7. Thus, it is possible that metformin affects HGP through this inter-organ crosstalk. Here we show that intraduodenal infusion of metformin for 50 min activated duodenal mucosal Ampk and lowered HGP in a rat 3 d high fat diet (HFD)-induced model of insulin resistance. Inhibition of duodenal Ampk negated the HGP-lowering effect of intraduodenal metformin, and both duodenal glucagon-like peptide-1 receptor (Glp-1r)–protein kinase A (Pka) signaling and a neuronal-mediated gut–brain–liver pathway were required for metformin to lower HGP. Preabsorptive metformin also lowered HGP in rat models of 28 d HFD–induced obesity and insulin resistance and nicotinamide (NA)–streptozotocin (STZ)–HFD-induced type 2 diabetes. In an unclamped setting, inhibition of duodenal Ampk reduced the glucose-lowering effects of a bolus metformin treatment in rat models of diabetes. These findings show that, in rat models of both obesity and diabetes, metformin activates a previously unappreciated duodenal Ampk–dependent pathway to lower HGP and plasma glucose levels.Keywords
This publication has 47 references indexed in Scilit:
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug PhenforminCancer Cell, 2013
- Overlap of Endocrine Hormone Expression in the Mouse Intestine Revealed by Transcriptional Profiling and Flow CytometryEndocrinology, 2012
- Cellular and molecular mechanisms of metformin: an overviewClinical Science, 2011
- Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy stateJCI Insight, 2010
- Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK ActivationCell Metabolism, 2010
- Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 DiabetesProceedings of the National Academy of Sciences of the United States of America, 2009
- Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in ratsJCI Insight, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contractionThe EMBO Journal, 2005
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001